Abstract
Danger signal was first proposed in 1994. In response to danger signal, dendritic cells, as the director of the T-cell immune system, would be matured and further enhance T-cell response. Hyaluronan had been reported as one of endogenous danger signals. Because of Seprafilm (most used for preventing post-operation adhesion) is also an hyaluronate-based agent, so we choose Seprafilm as our “candidate” of emerging danger signal to increasing T-cell response. We perform a pilot study in 10 ovarian cancer patients to compare the immune risk profiles between cases using Seprafilm (5 cases) and not using Seprafilm (5 cases). We found that there is no statistical difference on the immune risk profiles between two groups. However, a trend of increased CD4 in Seprafilm group was noted, indicating that Seprafilm might be an optional agent mimic danger signal. The potential value of Seprafilm to augment host immunosurveillance to improve survival rate in cancer patients is unknown, further study is needed to clarify the possibility of clinical applications.
Highlights
Most of the cases of ovarian cancer are diagnosed as advanced stage
Hyaluronan had been reported as one of endogenous danger signals, so we choose Seprafilm as our “candidate” of emerging danger signal to increasing T-cell response in ovarian cancer patients
In 5-year-survival, 3 patients in Seprafilm group were over 5 years and none in nonSeprafilm group had survival over 5 years
Summary
Most of the cases of ovarian cancer are diagnosed as advanced stage. There is 70% to 80% of complete remission after standard treatment (including debulking surgery, chemotherapy and radiotherapy), they still face 60% to 70% chance of disease relapse. Once relapse, they suffer from detrimental outcome following first-line treatment [1]. We urgently need better therapy, and how to augment the host immunosurveillance may be the way forward. Hyaluronan had been reported as one of endogenous danger signals, so we choose Seprafilm as our “candidate” of emerging danger signal to increasing T-cell response in ovarian cancer patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Nuclear Medicine & Radiation Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.